Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

AIM

AIM ImmunoTech Inc

Nov 20 • 04:00PM ET

1.30

-0.03 -2.26 %

Healthcare • Biotechnology • USA • AMEX

Peers: JNJ LLY PFE AZN MRNA BMY GILD AMGN REGN VRTX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-20.16	Insider Own	17.08%	Shs Outstand	2.76M	Perf Week	-11.26%
Market Cap	3.71M	Forward P/E	-	EPS next Y	-3.38	Insider Trans	0.00%	Shs Float	2.74M	Perf Month	-49.61%
Enterprise Value	3.64M	PEG	-	EPS next Q	-0.97	Inst Own	3.76%	Short Float	1.06%	Perf Quarter	-51.85%
Income	-15.75M	P/S	33.73	EPS this Y	78.03%	Inst Trans	1.88%	Short Ratio	0.29	Perf Half Y	-84.71%
Sales	0.11M	P/B	-	EPS next Y	50.37%	ROA	-165.08%	Short Interest	0.03M	Perf YTD	-93.43%
Book/sh	-2.20	P/C	1.54	EPS next 5Y	62.69%	ROE	-3138.91%	52W High	36.00 -96.39%	Perf Year	-94.36%
Cash/sh	0.84	P/FCF	-	EPS past 3/5Y	8.53% 34.59%	ROIC	-	52W Low	1.30 0.00%	Perf 3Y	-97.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	7.99% 3.96%	Gross Margin	-191.07%	Volatility	7.97% 10.16%	Perf 5Y	-99.36%
Dividend TTM	-	EV/Sales	33.09	EPS Y/Y TTM	57.35%	Oper. Margin	-12382.14%	ATR (14)	0.16	Perf 10Y	-99.98%
Dividend Ex-Date	-	Quick Ratio	0.64	Sales Y/Y TTM	-41.05%	Profit Margin	-14062.50%	RSI (14)	21.82	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.64	EPS Q/Q	75.55%	SMA20	-28.52%	Beta	1.30	Target Price	15.00
Payout	-	Debt/Eq	-	Sales Q/Q	-25.71%	SMA50	-43.73%	Rel Volume	0.25	Prev Close	1.33
Employees	23	LT Debt/Eq	-	Earnings	Aug 15 BMO	SMA200	-80.43%	Avg Volume	99.92K	Price	1.30
IPO	Jul 15, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	54.00% -75.00%	Trades		Volume	24,794	Change	-2.26%

Nov-18-25 08:55AM	AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program (GlobeNewswire) -7.64%
Nov-10-25 08:55AM	AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire) -6.37%
Nov-04-25 09:05AM	AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire) -20.40%
Nov-03-25 08:55AM	AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue (GlobeNewswire)
Oct-23-25 08:51AM	Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions (Zacks)
12:02PM	Loading…
Oct-22-25 12:02PM	Bet On 5 Top-Ranked Stocks With Rising P/E (Zacks)
Oct-20-25 09:15AM	AIM ImmunoTech to Attend the 2025 Maxim Growth Summit (GlobeNewswire)
Oct-10-25 12:00PM	All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy (Zacks)
Sep-25-25 08:45AM	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors (GlobeNewswire)
Sep-22-25 09:00AM	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth (GlobeNewswire) +6.16%
Sep-21-25 09:10AM	Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM) (Insider Monkey)
Sep-04-25 11:00AM	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland (GlobeNewswire)
Aug-21-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +8.47%
Aug-15-25 09:00AM	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-14-25 08:55AM	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
06:55PM	Loading…
Aug-11-25 06:55PM	FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 09:00AM	AIM ImmunoTechs Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
09:00AM	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
Aug-04-25 09:00AM	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval (GlobeNewswire) +6.36%
Jul-31-25 09:00AM	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering (GlobeNewswire)
Jul-29-25 09:00AM	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -56.25%
Jul-28-25 09:00AM	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) -14.29%
Jul-02-25 08:55AM	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies (GlobeNewswire)
Jun-20-25 04:15PM	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements (GlobeNewswire) +10.96%
Jun-17-25 08:55AM	AIM ImmunoTech Resumes Trading on NYSE American (GlobeNewswire) +6.84%
Apr-07-25 01:26PM	AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market (GlobeNewswire) -57.53%
Apr-04-25 04:45PM	AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal (GlobeNewswire) -19.37%
Mar-27-25 08:05AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	Apr 04 '25	Buy	0.06	41,000	2,583	1,899,029	Apr 07 03:42 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Apr 04 '25	Buy	0.09	500	44	401,762	Apr 04 05:19 PM
Equels Thomas K	CEO & President	Mar 05 '25	Buy	0.13	50,000	6,730	1,858,029	Mar 06 09:36 AM
Equels Thomas K	CEO & President	Mar 04 '25	Buy	0.12	44,000	5,060	1,808,029	Mar 05 10:00 AM
Equels Thomas K	CEO & President	Mar 04 '25	Buy	0.12	83,334	10,000	1,764,029	Mar 04 01:14 PM
MITCHELL WILLIAM M	Director	Dec 19 '24	Sale	0.19	4,580	884	118,549	Dec 20 04:30 PM
Equels Thomas K	CEO & President	Dec 18 '24	Buy	0.21	22,727	4,682	1,680,695	Dec 19 01:38 PM
APPELROUTH STEWART	Director	Dec 02 '24	Buy	0.21	11,112	2,356	355,509	Dec 04 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience